mitomycin c/悪性腫瘍

FIELD OF THE INVENTION The present invention relates to chemotherapeutic agents for treating cancer. BACKGROUND Cancer cells proliferate more rapidly than normal cells. The rate of mitosis and DNA replication is therefore significantly greater in cancer cells. Agents that inhibit DNA replication and

TECHNICAL FIELD The present invention is related to the field of molecular and experimental oncology, in particular to the description of a pharmaceutical combination directed to the treatment and/or chemosensibilization of refractory tumors to convencional cytostatics. PRIOR ART In the last three

TECHNICAL FIELD The present invention is related to the field of molecular and experimental oncology, in particular to the description of a pharmaceutical combination directed to the treatment and/or chemosensibilization of refractory tumors to convencional cytostatics. PRIOR ART In the last three

1. FIELD OF THE INVENTION The present invention is directed to administration of an nitric oxide (NO) scavenger or an NO synthase inhibitor to enhance the effectiveness of tumor therapy with hypoxic or acidic chemotherapeutic agents or hyperthermia. 2. BACKGROUND OF THE INVENTION 2.1 Hypoxic and

BACKGROUND OF THE INVENTION This invention relates to new derivatives of mitomycin C. The new derivatives of mitomycin C contemplated by the present invention are la-higher aliphatic acyl derivatives of mitomycin C having the general formula: ##STR2## wherein R is an aliphatic saturated or

TECHNICAL FIELD The subject matter described herein relates to methods for treating patients in need of treatment for a neoplastic condition by a combination of a liposomal prodrug of mitomycin C and a chemotherapeutic agent. BACKGROUND Cancer is a leading cause of death in the United States and

TECHNICAL FIELD The subject matter described herein relates to methods for treating patients in need of treatment for a neoplastic condition by a combination of a liposomal prodrug of mitomycin C and radiotherapy. BACKGROUND Cancer is a leading cause of death in the United States and affects people

1. FIELD OF THE INVENTION The present invention is directed to administration of a nitric oxide (NO) scavenger or an NO synthesis inhibitor as an antitumor therapy to reduce tumor blood flow and oxygenation or as an adjunct therapy to enhance the effectiveness of tumor therapy with hypoxic or acidic

FIELD OF THE INVENTION The present invention is directed to administration of a nitric oxide (NO) scavenger or an NO synthesis inhibitor as an antitumor therapy to reduce tumor blood flow and oxygenation or as an adjunct therapy to enhance the effectiveness of tumor therapy with hypoxic or acidic

FIELD OF THE INVENTION The present invention relates to a method for reducing the cytotoxicity of mitomycin C, and to a method of administering mitomycin C to a multi-drug resistant cell. Mitomycin C is provided in the form of a prodrug conjugate comprised of a hydrophobic moiety linked to the drug

FIELD OF THE INVENTION The present compounds are mitomycin C analogs (Class 548, Subclass 422) in which the 7-amino group is substituted by a disulfide containing organic group. These compounds are inhibitors of experimental animal tumors. BACKGROUND OF THE INVENTION Nomenclature--The systematic

BACKGROUND OF THE INVENTION This invention relates to an adminiculum for use in administering mitomycin C and doxorubicin. Mitomycin C, blue-violet crystals or crystalline powder of molecular formula C.sub.15 H.sub.18 N.sub.4 O.sub.5, combines with tumor cell DNA and degrades it. It also inhibits

FIELD OF THE INVENTION The present invention refers to mitomycin analogs containing two different amidino groups (Class 260 Subclass 326.24). These compounds are mitomycin C derivatives in which both the quinone amino group and the carbamido nitrogen atom are incorporated within an amidino

BACKGROUND OF THE INVENTION This invention is concerned with a new antitumor antibiotic complex and processes for production, recovery and separation into bioactive components. Based on present spectral data and available physico-chemical properties, the antitumor antibiotic complex of the present

TECHNICAL FIELD The present invention relates to mitomycin derivatives having anti-tumour activity and pharmaceutical compositions containing the same. BACKGROUND ART Mitomycins have excellent anti-tumour activity, whilst they are liable to exhibit certain undesired side effects such as the decrease